JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB108557

Recombinant human DLL4 protein (Fc Chimera Active)

Be the first to review this product! Submit a review

|

(7 Publications)

Recombinant human DLL4 protein (Fc Chimera Active) is a Human Fragment protein, in the 1 to 529 aa range, expressed in HEK 293 cells, with >95%, < 0.01 EU/µg endotoxin level, suitable for SDS-PAGE, FuncS.

View Alternative Names

UNQ1895/PRO4341, DLL4, Delta-like protein 4, Drosophila Delta homolog 4, Delta4

6 Images
Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
  • FuncS

Unknown

Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)

Adipogenesis inhibition of 3T3L-1 cells.
3T3L-1 cells (mouse pre-adipocyte cells) were maintained in DMEM, supplemented with 10% fetal bovine serum and penicillin-streptomycin. For differentiation of 3T3L-1 cells, 3T3L-1 cells were cultured in adipogenic medium which was growth medium supplemented with 1 μM Dexamethasone, 0.5 mM IBMX, 10 μg/ml lnsulin (day 0). Medium was changed every 2 days. Staining with Oil Red O was typically performed on day 7. Cells were washed twice with PBS, fixed with 3.7% formalin, and stained with 0.5% filtered Oil Red O in propylene glycol. For negative controls, mouse TNF-α (20 ng/ml) was added. Recombinant Human DLL4-Fc (ab108557) (5 μg/ml) dissolved in DPBS was added to the differentiation medium. These plates were then used to differentiate 3T3L-1 cells.

Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
  • FuncS

Unknown

Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)

Adipogenesis inhibition of 3T3L-1 cells.

Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
  • FuncS

Unknown

Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)

Adipogenesis inhibition of MSCs.
MSCs (Mesenchymal stem cells) were maintained in DMEM, supplemented with 10% fetal bovine serum, penicilinstreptomycin and glutamine. For differentiation of MSCs, MSCs were cultured in adipogenic medium which was growth medium supplemented with 1 μM Dexamethasone, 0.5mM IBMX, 10 μg/m lnsulin, 100 μM Indomethacin (day 1). Medium was changed every 3 days. Staining with Oil Red O was typically performed on day 30. For negative controls, TNF-α (20 ng/ml) was added. To immobilize Notch ligands on the plastic surface of the culture plates, plates were incubated with a solution of ab108557 (5 μg/ml) or mCD137-Fc (5 μg/ml) in PBS for 2 hours at 37°C. Plates were then used to differentiate MSCs.

Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
  • FuncS

Unknown

Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)

50 μg of cell lysates derived from hDLL4-Fc (ab108557) or non-treated 3T3L-1 cells, which had been either differentiated or undifferentiated, and were subjected to Western blot by using a Mouse adiponectin antibody.

Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
  • FuncS

Unknown

Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)

Interaction of Human Notch1 with Human DLL4.
HEK293 cells transfected with a Human Notch1 or a Human GITR ligand expressing vector were incubated with 25 μg/ml of Human GITR-Fc or ab108557. Cells were stained with anti-Human IgG (Fc specific) FITC conjugate for DLL4-Fc binding.

Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
  • FuncS

Unknown

Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)

Induction of Hes-1 with the treatment of recombinant Human DLL4-Fc (ab108557).

A Mouse preadpipocyte cell line, 3T3L-1, was stimulated with 5 μg/ml of Human DLL4-Fc as in indicated time points and each cell lysate was prepared and subjected to western blot by using anti-Mouse Hes1 or GAPDH.

M : Marker.
Lane 1 : hDLL4-Fc, 0 min.
Lane 2 : hDLL4-Fc, 10 min.
Lane 3 : hDLL4-Fc, 30 min.
Lane 4 : hDLL4-Fc, 1 hr.
Lane 5 : hDLL4-Fc, 2 hr.
Lane 6 : hDLL4-Fc, 4 hr.
Lane 7 : hDLL4-Fc, 8 hr.
Lane 8 : hDLL4-Fc, 24 hr.

Key facts

Purity

>95% SDS-PAGE

Endotoxin level

< 0.01 EU/µg

Expression system

HEK 293 cells

Tags

Fc tag C-Terminus

Applications

SDS-PAGE, FuncS

applications

Biologically active

Yes

Biological activity

Inhibits adipogenesis of 3T3L-1 cells and mesenchymal stem cells (MSCs). Induces the Notch target gene HES-1 when coated on a plate at 1μg/ml.

Accession

Q9NR61

Animal free

No

Carrier free

No

Species

Human

Reconstitution

Reconstitute in 100 µL of water

Storage buffer

Constituents: PBS, 0.5% Trehalose

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "FuncS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

ab108557 interacts with Human Notch1 (as confirmed by Flow Cytometry).

Sequence info

[{"sequence":"","proteinLength":"Fragment","predictedMolecularWeight":"80 kDa","actualMolecularWeight":null,"aminoAcidEnd":529,"aminoAcidStart":1,"nature":"Recombinant","expressionSystem":"HEK 293 cells","accessionNumber":"Q9NR61","tags":[{"tag":"Fc","terminus":"C-Terminus"}]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
True

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

DLL4 also known as Delta-like ligand 4 is a member of the Delta/Serrate/Lag-2 family. This target is a single-pass type I membrane protein with a molecular weight of approximately 65 kDa. It features prominently in the vascular endothelium where it impacts angiogenic activity. DLL4 acts as a ligand for Notch receptors initiating a signaling cascade important to cell fate decisions. DLL4 expression occurs mainly on the arterial endothelium and the tumor vasculature highlighting its significance in angiogenesis.
Biological function summary

DLL4 engages in precise regulation of angiogenesis and vascular development. It participates in the Notch signaling pathway playing an integral role in controlling endothelial cell proliferation differentiation and migration. DLL4 does not operate in isolation; instead it functions as part of the Notch receptor-ligand complex. This relationship effectively regulates the sprouting of new blood vessels ensuring proper vascular patterning and functional blood supply.

Pathways

DLL4 links directly to the Notch signaling and VEGF (vascular endothelial growth factor) pathways both of which play critical roles in vascular development and homeostasis. Through the Notch pathway DLL4 interacts with Notch1 and Notch4 receptors facilitating communication that inhibits endothelial cell proliferation distinguishing it from other pro-angiogenic factors. Its relationship with the VEGF pathway allows DLL4 to modulate angiogenic processes balancing vessel sprouting by opposing excessive VEGF-induced activities.

Aberrations of DLL4 influence cancer and cardiovascular diseases. Overexpression and dysregulation of DLL4 have been observed in various cancers where it contributes to tumor angiogenesis promoting the growth and spread of cancer cells. In cardiovascular disorders dysfunctional DLL4 signaling impacts vascular development which can lead to fatal arteriovenous malformations. In these conditions DLL4 interacts with proteins like Notch1 and VEGF underlining its critical involvement in pathological angiogenesis and vessel formation.

Specifications

Form

Lyophilized

Additional notes

Purified using affinity chromatography.

General info

Function

Involved in the Notch signaling pathway as Notch ligand (PubMed : 11134954). Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting (PubMed : 20616313). Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types (By similarity). During spinal cord neurogenesis, inhibits V2a interneuron fate (PubMed : 17728344).

Product protocols

Target data

Involved in the Notch signaling pathway as Notch ligand (PubMed : 11134954). Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting (PubMed : 20616313). Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types (By similarity). During spinal cord neurogenesis, inhibits V2a interneuron fate (PubMed : 17728344).
See full target information DLL4

Additional targets

IGHG1

Publications (7)

Recent publications for all applications. Explore the full list and refine your search

iScience 25:104306 PubMed35602952

2022

Engineered patterns of Notch ligands Jag1 and Dll4 elicit differential spatial control of endothelial sprouting.

Applications

Unspecified application

Species

Unspecified reactive species

Laura A Tiemeijer,Tommaso Ristori,Oscar M J A Stassen,Jaakko J Ahlberg,Jonne J J de Bijl,Christopher S Chen,Katie Bentley,Carlijn V C Bouten,Cecilia M Sahlgren

Clinical cancer research : an official journal of the American Association for Cancer Research 26:669-678 PubMed31672772

2019

EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Marius Bill,Aparna Pathmanathan,Malith Karunasiri,Changxian Shen,Matthew H Burke,Parvathi Ranganathan,Dimitrios Papaioannou,Nina C Zitzer,Katiri Snyder,Allison LaRocco,Allison E Walker,Zachary J Brannan,Ansel P Nalin,Aharon G Freud,Mikhail M Dikov,Xiaoli Zhang,Clara D Bloomfield,Ramiro Garzon,Adrienne M Dorrance

Cellular signalling 54:130-138 PubMed30529759

2018

A non-canonical JAGGED1 signal to JAK2 mediates osteoblast commitment in cranial neural crest cells.

Applications

Unspecified application

Species

Unspecified reactive species

Archana Kamalakar,Melissa S Oh,Yvonne C Stephenson,Samir A Ballestas-Naissir,Michael E Davis,Nick J Willett,Hicham M Drissi,Steven L Goudy

Scientific reports 8:6392 PubMed29686270

2018

Spatial patterning of the Notch ligand Dll4 controls endothelial sprouting in vitro.

Applications

Unspecified application

Species

Unspecified reactive species

L A Tiemeijer,J-P Frimat,O M J A Stassen,C V C Bouten,C M Sahlgren

Scientific reports 7:43926 PubMed28266574

2017

Notch1 Signaling Contributes to Hypoxia-induced High Expression of Integrin β1 in Keratinocyte Migration.

Applications

Unspecified application

Species

Unspecified reactive species

Di Tang,Tiantian Yan,Junhui Zhang,Xupin Jiang,Dongxia Zhang,Yuesheng Huang

Oncotarget 6:22467-79 PubMed26093085

2015

DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation.

Applications

Unspecified application

Species

Unspecified reactive species

Monica Faronato,Van T M Nguyen,Darren K Patten,Ylenia Lombardo,Jennifer H Steel,Naina Patel,Laura Woodley,Sami Shousha,Giancarlo Pruneri,R Charles Coombes,Luca Magnani

The Journal of biological chemistry 289:12016-28 PubMed24599951

2014

Endothelial Kruppel-like factor 4 regulates angiogenesis and the Notch signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Andrew T Hale,Hongmei Tian,Ejike Anih,Fernando O Recio,Mohammad A Shatat,Trent Johnson,Xudong Liao,Diana L Ramirez-Bergeron,Aaron Proweller,Masakazu Ishikawa,Anne Hamik
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com